Cargando…

Anti-vascular agent Combretastatin A-4-P modulates Hypoxia Inducible Factor-1 and gene expression

BACKGROUND: A functional vascular network is essential for the survival, growth and spread of solid tumours, making blood vessels a key target for therapeutic strategies. Combretastatin A-4 phosphate (CA-4-P) is a tubulin-depolymerising agent in Phase II clinical trials as a vascular disrupting agen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dachs, Gabi U, Steele, Andrew J, Coralli, Claudia, Kanthou, Chryso, Brooks, Andrew C, Gunningham, Sarah P, Currie, Margaret J, Watson, Ally I, Robinson, Bridget A, Tozer, Gillian M
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1702548/ https://www.ncbi.nlm.nih.gov/pubmed/17156434 http://dx.doi.org/10.1186/1471-2407-6-280

Ejemplares similares

The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate
por: Holmes, Toby, et al.
Publicado: (2020)

The protective role of sphingosine-1-phosphate against the action of the vascular disrupting agent combretastatin A-4 3-O-phosphate
por: Shepherd, Joanna, et al.
Publicado: (2017)

Tumour Cells Expressing Single VEGF Isoforms Display Distinct Growth, Survival and Migration Characteristics
por: Kanthou, Chryso, et al.
Publicado: (2014)

An in vivo role for Rho kinase activation in the tumour vascular disrupting activity of combretastatin A-4 3-O-phosphate
por: Williams, L J, et al.
Publicado: (2014)

Do Anti-Angiogenic VEGF (VEGFxxxb) Isoforms Exist? A Cautionary Tale
por: Harris, Sheila, et al.
Publicado: (2012)

Effect of post-implant exercise on tumour growth rate, perfusion and hypoxia in mice
por: Buss, Linda A., et al.
Publicado: (2020)

Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide
por: Parkins, C S, et al.
Publicado: (2000)

Gene delivery to hypoxic cells in vitro
por: Dachs, G U, et al.
Publicado: (2000)

Wearable Insulin Biosensors for Diabetes Management: Advances and Challenges
por: Psoma, Sotiria D., et al.
Publicado: (2023)

Increased Tumor Ascorbate is Associated with Extended Disease-Free Survival and Decreased Hypoxia-Inducible Factor-1 Activation in Human Colorectal Cancer
por: Kuiper, Caroline, et al.
Publicado: (2014)

Combretastatin-Inspired Heterocycles as Antitubulin Anticancer Agents
por: Hura, Neha, et al.
Publicado: (2018)

Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study
por: Gaya, A, et al.
Publicado: (2008)

Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells
por: VOLKOVA, EKATERINA, et al.
Publicado: (2014)

Direct visualization of electroporation-assisted in vivo gene delivery to tumors using intravital microscopy – spatial and time dependent distribution
por: Cemazar, Maja, et al.
Publicado: (2004)

The Association Between Ascorbate and the Hypoxia-Inducible Factors in Human Renal Cell Carcinoma Requires a Functional Von Hippel-Lindau Protein
por: Wohlrab, Christina, et al.
Publicado: (2018)

Activation of the hypoxia pathway in breast cancer tissue and patient survival are inversely associated with tumor ascorbate levels
por: Campbell, Elizabeth J., et al.
Publicado: (2019)

Development of Combretastatin A-4 Analogues as Potential Anticancer Agents with Improved Aqueous Solubility
por: Chen, Zhi-Hao, et al.
Publicado: (2023)

Effect of immune modulation on the skeletal muscle mitochondrial exercise response: An exploratory study in mice with cancer
por: Buss, Linda A., et al.
Publicado: (2021)

Cytotoxicity Studies of Novel Combretastatin and Pterostilbene Derivatives
por: Jakubowska, Joanna, et al.
Publicado: (2014)

Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate
por: Ibrahim, Mohamed A, et al.
Publicado: (2013)

The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells
por: Dey, Sanchareeka, et al.
Publicado: (2017)

Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation
por: Kelly, Patrick M., et al.
Publicado: (2017)

Design, Synthesis, and Biological Evaluation of Novel Pyridine-Bridged Analogues of Combretastatin-A4 as Anticancer Agents
por: Zheng, Shilong, et al.
Publicado: (2014)

Exploring Diverse-Ring Analogues on Combretastatin A4 (CA-4) Olefin as Microtubule-Targeting Agents
por: Song, Ming-Yu, et al.
Publicado: (2020)

Pharmacokinetic Profile Evaluation of Novel Combretastatin Derivative, LASSBio-1920, as a Promising Colorectal Anticancer Agent
por: Guimarães, Celina de Jesus, et al.
Publicado: (2023)

Imidazole Analogs of Vascular-Disrupting Combretastatin A-4 with Pleiotropic Efficacy against Resistant Colorectal Cancer Models
por: Reipsch, Franziska, et al.
Publicado: (2021)

Novel indole-bearing combretastatin analogues as tubulin polymerization inhibitors
por: Kumar, Sunil, et al.
Publicado: (2013)

Combretastatin A4 disodium phosphate-induced myocardial injury
por: Tochinai, Ryota, et al.
Publicado: (2016)

Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications
por: Karatoprak, Gökçe Şeker, et al.
Publicado: (2020)

Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue
por: Griggs, J, et al.
Publicado: (2001)

The interaction with tubulin of a series of stilbenes based on combretastatin A-4.
por: Woods, J. A., et al.
Publicado: (1995)

The anti-angiogenic effect and novel mechanisms of action of Combretastatin A-4
por: Su, Min, et al.
Publicado: (2016)

Synthesis and Cytotoxic Activity of a New Group of Heterocyclic Analogues of the Combretastatins
por: Lipeeva, Alla V., et al.
Publicado: (2014)

Ascorbate modulates the hypoxic pathway by increasing intracellular activity of the HIF hydroxylases in renal cell carcinoma cells
por: Wohlrab, Christina, et al.
Publicado: (2019)

A profile of prognostic and molecular factors in European and Māori breast cancer patients
por: Dachs, Gabi U, et al.
Publicado: (2010)

Gene and Protein Expression Is Altered by Ascorbate Availability in Murine Macrophages Cultured under Tumour-Like Conditions
por: Ang, Abel D., et al.
Publicado: (2021)

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
por: Grosios, K, et al.
Publicado: (1999)

Combretastatin A-4 efficiently inhibits angiogenesis and induces neuronal apoptosis in zebrafish
por: Shi, Yun-Wei, et al.
Publicado: (2016)

Galactose Modified Liposomes for Effective Co-Delivery of Doxorubicin and Combretastatin A4
por: Lian, Bo, et al.
Publicado: (2021)

Combretastatin A4-camptothecin micelles as combination therapy for effective anticancer activity
por: Assali, Mohyeddin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vcfbupkvlc9ttl7h7dv1k5h5je